Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives $29.00 Consensus Target Price from Analysts

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $29.00.

Several research analysts have issued reports on the company. The Goldman Sachs Group set a $24.00 price target on Kestra Medical Technologies in a report on Friday, January 16th. BTIG Research initiated coverage on Kestra Medical Technologies in a report on Tuesday, November 18th. They set a “buy” rating and a $32.00 target price for the company. Wells Fargo & Company increased their price target on Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Stifel Nicolaus set a $30.00 price objective on Kestra Medical Technologies in a report on Friday, December 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Wednesday, December 24th.

Kestra Medical Technologies Stock Performance

Shares of KMTS opened at $24.67 on Friday. Kestra Medical Technologies has a 12-month low of $13.25 and a 12-month high of $30.00. The stock has a market capitalization of $1.44 billion and a P/E ratio of -7.78. The firm’s 50 day moving average is $25.42 and its 200-day moving average is $22.69. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.47 and a quick ratio of 5.47.

Insider Activity at Kestra Medical Technologies

In other news, insider Traci S. Umberger sold 10,500 shares of Kestra Medical Technologies stock in a transaction on Monday, December 29th. The stock was sold at an average price of $26.69, for a total transaction of $280,245.00. Following the transaction, the insider owned 136,633 shares in the company, valued at approximately $3,646,734.77. The trade was a 7.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $22.80, for a total value of $342,000.00. Following the transaction, the insider directly owned 394,786 shares in the company, valued at $9,001,120.80. The trade was a 3.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 40,500 shares of company stock worth $1,021,095. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Large investors have recently made changes to their positions in the business. Jennison Associates LLC lifted its position in shares of Kestra Medical Technologies by 15.0% in the fourth quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock worth $5,817,000 after purchasing an additional 28,573 shares in the last quarter. UBS Group AG lifted its position in Kestra Medical Technologies by 34.9% in the 4th quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after buying an additional 69,908 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in shares of Kestra Medical Technologies during the 4th quarter valued at $31,000. Millennium Management LLC increased its stake in shares of Kestra Medical Technologies by 534.7% in the third quarter. Millennium Management LLC now owns 219,706 shares of the company’s stock worth $5,220,000 after acquiring an additional 185,090 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Kestra Medical Technologies during the third quarter worth $185,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.